GLP-1 Market
LLY $1157.49 ▲ +1.3% NVO $37.53 ▼ -0.0% PFE $27.50 ▲ +0.3% VKTX $28.38 ▼ -3.1% KLRA $10.83 ▼ -0.1% GPCR $27.47 ▼ -0.4% RHHBY $52.55 ▲ +0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HRS-4729

HRS-4729

Company
Fujian Shengdi Pharmaceutical Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 7, 2026

Find a Clinical Trial Near Me

See recruiting studies for HRS-4729 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07660848

    A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 160 participants Est. completion 2028-07 2 sites Stand-alone
    MASH
    View official trial listing →
  • Recruiting NCT NCT07807059

    A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 32 participants Est. completion 2027-03-15 1 site Stand-alone
    MASHMASLDType 2 diabetes Other conditions: Overweight/Obesity
    View official trial listing →
  • Completed NCT NCT06762600

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 102 participants Est. completion 2026-03-12 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07690826

    A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 252 participants Est. completion 2027-07 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07843862

    A Study of HRS-4729 Injection in Participants With Type 2 Diabetes

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 240 participants Est. completion 2027-07 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: HRS-4729, HRS-4729 Injection

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.